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Leukotriene B4 (LTB4) is a potent inflammatory mediator in asthma, and is increased in more
severe asthma. Targeting LTB4, in addition to cysteinyl leukotrienes, could be beneficial in
asthma.
This was a randomized, double-blind trial of once-daily MK-0633, a potent 5-lypoxygenase
inhibitor, 10 mg, 50 mg, and 100 mg, and placebo in patients 18e70 years with a history of
chronic asthma, and FEV1 45 and 85% predicted. There was a 6-week main period and
optional 18-week and 34-week periods (52 weeks total), the latter two comparing only MK-
0633 100 mg and placebo. The primary endpoint was the change from baseline in FEV1 over
the last 4 weeks of the 6-week primary treatment period. Secondary endpoints included
symptom scores, b-agonist use, peak expiratory flow (PEF), asthma quality of life question-
naire (AQLQ), asthma control questionnaire (ACQ), asthma attacks, exacerbations, days with
asthma control, post-b-agonist FEV1, and blood eosinophils.
MK-0633 100 mg was significantly more effective than placebo for the change from baseline
in FEV1 (0.20 L vs. 0.13 L; p Z 0.004). The other MK-0633 doses were not significantly more
effective than placebo. MK-0633 (at various doses) was also more effective than placebo for
b-agonist use, AQLQ, AM and PM PEFR, ACQ, and post-b-agonist FEV1 (p < 0.05 for all). MK-
0633 was associated with a dose-dependent increase in elevated aspartate aminotransferase
and alanine aminotransferase.& Dohme Corp , 2000 Galloping Hill Road , K15-4,4455, Kenilworth, NJ 07033, USA. Tel.: þ1 908 740
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unblinding for the main study period. Overall, the benefit-risk ratio did not support the clinical
utility of MK-0633 in asthma.
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Despite advances in asthma management and education
initiatives, the proportion of patients achieving adequate
asthma control continues to be suboptimal.1,2 In one study
specifically designed to evaluate guideline-based asthma
treatments in patients with uncontrolled asthma, after
a year of treatment, fewer than 75% of patients had well-
controlled asthma, and only approximately one-third ach-
ieved total asthma control, even though most patients were
receiving the maximum doses of either inhaled fluticasone
or inhaled fluticasone plus salmeterol.3 In addition, a cross
sectional study in Canada evaluating asthma control (as
defined by healthcare resource utilization, b-agonist use,
nighttime awakenings, and missed school or work) revealed
that asthma control did not improve between 1997 and
2002.4 Thus, there continues to be a need for new thera-
peutic options in asthma.
The central role of leukotrienes in asthma is well-
established.5 5-lipoxygenase (5-LO) and 5-LO activating
protein (FLAP) catalyze the conversion of arachidonic acid
to leukotriene A4 (LTA4), which in one pathway is converted
to LTB4, and in another pathway to LTC4, which is further
converted to LTD4 and LTE4.
5,6 LTC4, LTD4, and LTE4,
collectively known as the cysteinyl leukotrienes (CysLTs),
are produced primarily by mast cells, macrophages, and
eosinophils, and play a key role in bronchoconstriction,
airway edema and mucus secretion. LTB4, on the other
hand, is synthesized primarily by neutrophils and is a potent
chemoattractant and inflammatory mediator thought to
play a significant role in early immune system activation
and T-cell recruitment,7 as well as neutrophil and macro-
phage recruitment and activation.8,9
LTB4 may be a particularly important mediator in more
severe asthma. Studies have demonstrated that, compared
to patients with mild to moderate asthma, patients with
severe asthma had significantly increased concentrations of
neutrophils in bronchoalveolar lavage,10 and induced
sputum.11,12 Clinically, the potential role of neutrophils and
LTB4 in severe asthma is supported by a post-hoc analysis of
two studies of the 5-LO inhibitor zileuton, which showed
substantially greater effects versus placebo on forced
expiratory volume in 1 s (FEV1) and on the percentage of
patients requiring oral corticosteroid rescue in patients
with severe asthma (baseline FEV1 50% predicted)
compared with the full patient cohort.13,14
These results also highlight the potential utility of
inhibiting leukotriene synthesis (i.e., 5-LO or FLAP), and
thus inhibiting both LTB4 and CysLTs. Given the distinct
effects of CysLTs and LTB4 in asthma, an agent that inhibits
both products would theoretically confer greater protec-
tion in chronic asthma, with the potential for enhanced
efficacy among severe asthmatics. Zileuton is the only
leukotriene synthesis inhibitor approved to date. Its use hasbeen limited hepatic enzyme monitoring and q.i.d.
dosing,14 although it is now available as a controlled-
release, b.i.d. formulation.
The purpose of this Phase II trial was to evaluate the
efficacy and tolerability of MK-0633, a potent, once-daily 5-
LO inhibitor, in adults with chronic asthma.
Methods
Full methodological details are available in the Online
Supplementary material.
Patients
Men and women age 18e70 years with a history of chronic
asthma for at least 1 year were eligible. Patients had FEV1
45% and 85% of the predicted value, and reversibility of
12% within 20e30 min following b-agonist administration.
To determine the efficacy of MK-0633 across the spectrum
of asthma severity, patients were stratified as being
treated with either (1) a stable dose of inhaled cortico-
steroid (ICS) or an ICS and long-acting b-agonist (LABA)
combination for at least 4 weeks preceding screening
(approximately 2/3 of subjects, who continued with this
concomitant therapy at a stable dose during the trial), or
(2) only as-needed short-acting b-agonists (approximately
1/3 of subjects). This stratification plan was chosen to
maximize the percentage of patients with more severe
asthma that was not adequately controlled, which was the
primary population of interest. Excluded asthma medica-
tions included inhaled long-or short-acting anticholinergic
agents within 2 weeks; ICS within 4 weeks of the screening
visit, or oral or inhaled LABAs within 1 week (if patient was
not included in the 2/3 of patients in the ICS or ICS/LABA
group); oral, intravenous, intramuscular, or rectal cortico-
steroids within 4 weeks; xanthine derivatives or combina-
tions within 2 weeks, antileukotrienes within 2 weeks, or
omalizumab within 4 weeks.
Inhaled albuterol/salbutamol was permitted on an as-
needed basis for relief of asthma symptoms. An action plan
for worsening asthma was provided.
Study design (Fig. 1)
This study (Merck Protocol 007, ClinicalTrials.gov identifier
NCT00404313) was a 6-week, multicenter, randomized,
double-blind, placebo-controlled, parallel group, dose-
ranging study of MK-0633, conducted at 154 multinational
sites from March 2008 to June 2009. The study was con-
ducted in accordance with principles of Good Clinical
Practice and was approved by the appropriate institutional
review boards and regulatory agencies. All patients
provided written informed consent prior to participation.
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Figure 1 Study design.
36 Y.S. Wasfi et al.During a 2-week, single-blind, placebo run-in period
(Period I), patients were required to meet minimum asthma
symptom requirements and have at least 80% compliance
with study medication as determined by pill count. Eligible
patients were randomized to once-nightly MK-0633 10 mg,
50 mg, 100 mg, or matching placebo for 6 weeks (Period II).
Two optional double-blind extensions comparing MK-0633
100 mg and placebo followed: an 18-week (24 weeks total)
extension (Period III), and a 34-week (52 weeks total)
extension (Period IV). Patients on active treatment (any
dose) in Period II received MK-0633 (100 mg) in Periods III
and IV, and patients receiving placebo in Period II continued
to receive placebo in Periods III and IV.
Allocation was determined according to a computer-
generated schedule. Numbered vials were used to imple-
ment allocation. All study personnel, including investiga-
tors, study site personnel, patients, monitors, and central
laboratory personnel remained blinded to treatment allo-
cation throughout the study. The code was revealed to the
researchers once recruitment, data collection, and labo-
ratory analyses were complete.Efficacy and tolerability assessments
Spirometry was performed in accordance with ATS criteria
standards of acceptability and quality control.15 A standard
spirometer (NDD) was provided. Measurements were per-
formed at baseline/randomization and at weeks 1, 2, 4, 5,
and 6 between 6 AM and 10 AM after withholding short-acting
b-agonists for at least 6 h, ICS for at least 12 h, and ICS/LABA
for at least 14 h. The largest FEV1 and FVC from acceptable
and reproducible maneuvers were used for the analyses. A
daily patient diary was used to capture daytime and night-
time symptoms, b-agonist use, peak expiratory flow rate
(PEFR), and asthma resource utilization. Patients also
completed the AsthmaQuality of life Questionnaire (AQLQ)16
and Asthma Control Questionnaire (ACQ).17
The primary efficacy endpoint was the change from
baseline in FEV1 (pre-b-agonist) over the last 4 weeks of the
6-week treatment period. Secondary endpoints were the
change from baseline in daytime and nighttime symptom
scores over the last 4 weeks of treatment. Other endpoints
included as-needed b-agonist use, AM and PM PEFR, change
in AQLQ and ACQ scores, the percentage of patients with
asthma attacks, asthma exacerbations, percentage of dayswith asthma control; post-b-agonist FEV1; and average total
peripheral blood eosinophils counts. Exploratory endpoints
included the pharmacokinetic measurements of MK-0633,
change from baseline in urine LTE4 excretion, and plasma
biomarkers [e.g., immunoglobulin E (IgE) and eosinophilic
cationic protein (ECP)].
Tolerability was assessed by physical and laboratory
examinations, vital signs, and incidence of adverse expe-
riences (AEs). Because of a suggestion of renal tubular
damage in mice in acute toxicity studies, an internal data
safety monitoring committee reviewed results of an interim
blinded safety analysis of urine N-acetyl-b-glucosaminidase
(NAG), a sensitive marker of acute tubular injury,18 as well
as other markers of renal function, after 50% of patients
completed the main study. Any patients found to have NAG
elevations >2 but <3 from baseline at this blinded
interim analysis had their urinary monitoring increased to
every 1e2 weeks; patients with NAG >3 baseline value on
2 consecutive measurements were discontinued. Patients
with ALT or AST 3 ULN on 2 consecutive occasions were
also discontinued.
Pharmacokinetic (PK) measurements
Plasma samples were collected for MK-0633 assay at pre-
study and at week 6, pre-dose. Urinary LTE4 samples were
collected at baseline and at Week 6.
Statistical methods
The primary hypothesis was that MK-0633, compared with
placebo,would result in significant improvement in FEV1 over
the last 4 weeks (weeks 2, 4, 5, and 6) of the 6-week active
treatment period. Theprimaryefficacy analysiswasbasedon
the Full Analysis Set population, which included all
randomized patients who received at least one dose of study
treatment and had a baseline and at least one on-treatment
FEV1 measurement. Patients were included in the treatment
group to which theywere randomized. The primary endpoint
was analyzed using weekly changes from baseline in a longi-
tudinal data analysis model with the Tukey linear trend test
for assessing doseeresponse, and included factors for
treatment, week, concomitant corticosteroid stratum
(none, either ICS or ICS/LABA), and baseline value as cova-
riates. The analyses were based on observed data; missing
The efficacy and tolerability of Mk-0633, a 5-lipoxygenase inhibitor, in chronic asthma 37values were not imputed. Pre-specified subgroup analyses
included gender, age (, >median), age and gender
combined, race (white, black, Hispanic, Asian, other), region
(US/Canada, Central/South America, Europe, Japan, other),
baseline FEV1 % predicted (, >median), severe persistent
asthma as defined by the National Asthma Education and
Prevention Program (NAEPP) guidelines19 (yes/no); and
severe persistent asthma as defined by the Global Initiative
for Asthma (GINA) guidelines20 (yes/no). A per-protocol
analysis would be performed only if more than 5% of
patients in the FAS population were protocol violators.
Tolerability analyses were based on the All Patients as
Treated population, which included all randomized patients
who received at least one dose of study medication.Continued to  
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Figure 2 Patient floPatients were included in the treatment group corre-
sponding to the study medication actually received, irre-
spective of the group to which they were randomized. AEs
of interest included discontinuations due to worsening of
asthma, the percentage of patients meeting NAG criterion
for discontinuation, and the percentage of patients with
percent change in urinary NAG and microalbumin of <100%;
100% to <200%; and 200%. We also collected rates of
clinical AEs, drug-related AEs, serious AEs, and discontin-
uations due to AEs.
The MK-0633 doses were compared with placebo using
a stepwise linear trend test, which was dependent on
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38 Y.S. Wasfi et al.Because there was only one primary endpoint, and because
all other endpoints were considered supportive or explor-
atory, no further adjustment formultiplicity was performed.
With the planned 180 evaluable patients per group, the
study had 92% power (aZ 0.05, two-sided t-test) to detect
a 0.12 L treatment difference between an active group and
placebo in the change from baseline in FEV1, assuming
a standard deviation of 0.34 L. In the subgroup of patients
receiving ICS or ICS/LABA (planned to be 120 evaluable
patients per group), the study had 80% power (a Z 0.10,
two-sided t-test) to detect a 0.11 L difference in change
from baseline in FEV1.
Results
Patients
Patient flow through study is shown in Fig. 2. Approximately
90% of patients in each treatment group completed thebase study (Period II). The most common reason for
discontinuation from the study was early study termination
by the sponsor. Baseline patient demographics were similar
among treatment groups (Table 1).Efficacy
Period II e 6 weeks
For the primary endpoint of the change from baseline in
FEV1 over the last 4 weeks of treatment, there was
a statistically significant improvement from placebo
through MK-0633 100 mg (pZ 0.004 by the trend test), but
not for MK-0633 50 mg (Table 2). The maximal effect was
attained by Week 2 and remained generally stable through
Week 6 (Fig. 3A). In general, the efficacy for the primary
endpoint by concomitant medication stratum (i.e., ICS or
ICS/LABA, none) was consistent for a given MK-0633 dose,
as well as for other pre-specified subgroups (data not
shown).
Table 1 Baseline patient characteristics - All randomized patients.
Placebo N Z 239 MK-0633 10 mg N Z 239 MK-0633 50 mg N Z 238 MK-0633 100 mg N Z 238
Sex, n (%)
Female 155 (64.9) 154 (64.4) 137 (57.6) 139 (58.4)
Age (years)
Mean (SD) 44.0 (14.5) 43.2 (13.9) 43.6 (13.0) 42.8 (12.9)
Range 18.0 to 70.0 18.0 to 69.0 18.0 to 70.0 19.0 to 70.0
Body Mass Index (kg/m2)
Mean (SD) 26.5 (4.7) 26.7 (5.2) 26.0 (4.3) 26.1 (4.4)
Race, n (%)
White 115 (48.1) 100 (41.8) 101 (42.4) 104 (43.7)
Black 9 (3.8) 13 (5.4) 14 (5.9) 6 (2.5)
Asian 62 (25.9) 69 (28.9) 71 (29.8) 73 (30.7)
Other 53 (22.2) 57 (23.8) 52 (21.8) 55 (23.1)
Smoking history, n (%)
Ex-smoker 42 (17.6) 32 (13.4) 37 (15.5) 36 (15.1)
Concomitant asthma medications, n (%)
None 84 (35.1) 84 (35.1) 87 (36.6) 88 (37.0)
ICS 76 (31.8) 86 (36.0) 74 (31.1) 77 (32.4)
ICS/LABA 79 (33.1) 69 (28.9) 77 (32.4) 73 (30.7)
FEV1, mean (SD)
L 2.03 (0.65) 2.02 (0.63) 2.07 (0.58) 2.04 (0.63)
% predicted 65.12 (10.89) 64.58 (10.73) 64.56 (10.52) 64.40 (11.62)
ICS: inhaled corticosteroid; LABA: long-acting b-agonist; SD: standard deviation.
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and placebo for the secondary endpoints of daytime or
nighttime symptom scores (Table 2). There was amodest but
significant reduction from baseline in total daily b-agonist
use through MK-0633 100 mg compared with placebo
(pZ 0.022). The differences from placebo for both AM and
PM PEFR were significant through both MK-0633 100 mg
(pZ 0.015andpZ 0.038, respectively) and 50mg (pZ 0.002
and p Z 0.018, respectively), as was the change in post-b-
agonist FEV1 (pZ 0.006 and pZ 0.029, respectively).
There were no significant differences between MK-0633
and placebo for measures of asthma control except for the
percentage of patients who received at least one oral,
intravenous, or intramuscular corticosteroid rescue in the
MK-0633 100 mg and 50 mg groups compared with placebo
(p Z 0.036 for both) (Table 3).
Compared with placebo, there was a significant
improvement in overall AQLQ through MK-0633 100 mg
(pZ 0.030) (Table 2) and significant improvements with all
MK-0633 doses for the AQLQ symptom domain (pZ 0.025 to
0.003) (data not shown). There were no significant differ-
ences in the other domains. There were significant differ-
ences through both MK-0633 100 mg (p  0.001) and 50 mg
(p Z 0.005) compared with placebo for change in overall
ACQ score (Table 2).
Period III e 24 weeks
MK-0633 100 mg was significantly more effective than
placebo for the change from baseline in FEV1 over Period III
(p Z 0.034) (Supplementary Table 1, Fig. 3b). The effect
appeared to plateau around Week 8 and remain stable
through Week 24. MK-0633 was significantly more effective
than placebo for AM PEFR (pZ 0.006), PM PEFR (pZ 0.004),
percentage of patients with at least one systemic cortico-
steroid rescue (pZ 0.020), overall AQLQ score (pZ 0.029),as well as the individual AQLQ domain scores of symptoms
score (p Z 0.005), emotions score (p Z 0.044), and envi-
ronment score (pZ 0.035) (data not shown), the ACQ score
(p Z 0.003), eosinophils count (p  0.001), and post-b-
agonist FEV1 (p Z 0.016) (Supplementary Tables 1 and 2).
There were no other significant differences between MK-
0633 100 mg and placebo in Period III.
Period IV e 52 weeks
Fig. 3b, Supplementary Figure 1, and Supplementary Table
3 summarize the results from Period IV. Because of the
limited data available for formal statistical analysis was not
performed on efficacy endpoints.
Pharmacokinetics-pharmacodynamics
At the end of Period II, compared with placebo, MK-0633
substantially decreased the LTE4/creatinine ratio in a dose-
related fashion; median values for the 10 mg, 50 mg, and
100 mg doses were 28.3%, 4.6%, and 3.5% of the baseline
values, respectively. By contrast, the LTE4/creatinine level
for placebo was essentially unchanged at 98.2% of the
baseline value. Maximal (i.e., 90% pre-dose) inhibition of
urinary LTE4 occurred with MK-0633 plasma concentrations
of approximately 1200 nM (Supplementary Fig. 2a).
However, this plasma concentration of MK-0633 was asso-
ciated with only small percentage change in FEV1
(Supplementary Figure 2b).
Tolerability
Period II e 6 weeks
The frequency of clinical AEs was generally similar between
treatment groups (Table 4). There were a total of 9 serious
Table 2 Main efficacy measures, Full analysis set, Period II.
Treatment N Baseline, mean (SD) Change from baseline, LS mean (95% CI) p-value vs. placebod
FEV1 (L)
a
Placebo 234 2.03 (0.65) 0.13 (0.09, 0.16) e
MK-0633 10 mg 232 2.02 (0.64) 0.14 (0.10, 0.18) 0.586
MK-0633 50 mg 232 2.07 (0.58) 0.16 (0.12, 0.20) 0.201
MK-0633 100 mg 234 2.04 (0.63) 0.20 (0.16, 0.24)e 0.004
Daytime symptom scorea
Placebo 233 2.39 (0.90) 0.25 (0.34, 0.15) e
MK-0633 10 mg 231 2.26 (0.80) 0.30 (0.40, 0.21) 0.404
MK-0633 50 mg 232 2.40 (0.85) 0.26 (0.36, 0.17) 0.828
MK-0633 100 mg 232 2.32 (0.78) 0.32 (0.42, 0.23) 0.369
Nighttime symptom scorea c
Placebo 188 0.71 (0.49) 0.19 (0.25, 0.14) e
MK-0633 10 mg 177 0.74 (0.49) 0.21 (0.27, 0.16) 0.652
MK-0633 50 mg 168 0.64 (0.43) 0.25 (0.31, 0.19) 0.130
MK-0633 100 mg 161 0.77 (0.50) 0.26 (0.32, 0.20) 0.072
Total daily b-agonist use (puffs/day)a
Placebo 233 3.55 (2.50) 0.70 (0.91, 0.48) e
MK-0633 10 mg 231 3.83 (3.07) 0.65 (0.86, 0.43) 0.734
MK-0633 50 mg 232 3.65 (2.66) 0.94 (1.16, 0.73) 0.114
MK-0633 100 mg 232 3.55 (2.31) 0.97 (1.18, 0.75)e 0.022
AM PEFR (L/s)a
Placebo 233 327.18 (104.03) 6.48 (2.28, 10.68) e
MK-0633 10 mg 231 326.91 (93.84) 9.26 (5.05, 13.48) 0.325
MK-0633 50 mg 232 336.75 (96.35) 15.22 (11.01, 19.44)e 0.002
MK-0633 100 mg 232 333.34 (100.75) 12.23 (8.04, 16.43) 0.015
PM PEFR (L/s)a
Placebo 233 315.08 (101.79) 9.18 (4.87, 13.49) e
MK-0633 10 mg 231 315.82 (92.18) 11.99 (7.66, 16.32) 0.337
MK-0633 50 mg 232 326.64 (94.67) 16.13 (11.81, 20.45) 0.018
MK-0633 100 mg 231 320.66 (99.50) 14.55 (10.24, 18.86) 0.038
Asthma Quality of Life Questionnaire, overall scoreb
Placebo 224 4.21 (1.13) 0.42 (0.31, 0.54) e
MK-0633 10 mg 221 4.32 (1.07) 0.56 (0.44, 0.67) 0.101
MK-0633 50 mg 217 4.28 (1.02) 0.58 (0.47, 0.70) 0.056
MK-0633 100 mg 219 4.41 (1.12) 0.60 (0.49, 0.72) 0.030
Asthma Control Questionnaire, overall scoreb
Placebo 226 2.41 (0.78) 0.35 (0.44, 0.25) e
MK-0633 10 mg 221 2.34 (0.78) 0.46 (0.55, 0.36) 0.103
MK-0633 50 mg 216 2.39 (0.71) 0.54 (0.64, 0.44) 0.005
MK-0633 100 mg 219 2.38 (0.81) 0.58 (0.68, e0.49) 0.001
Post-b-agonist FEV1 (L)
b
Placebo 210 2.50 (0.76) 0.04 (0.08, 0.00) e
MK-0633 10 mg 207 2.47 (0.75) 0.03 (0.07, 0.01) 0.817
MK-0633 50 mg 208 2.50 (0.66) 0.02 (0.02, 0.06) 0.029
MK-0633 100 mg 214 2.50 (0.72) 0.02 (0.02, 0.06)e 0.006
Eosinophils (103/microL)b
Placebo 213 0.35 (0.30) 0.03 (0.06, 0.00) e
MK-0633 10 mg 210 0.40 (0.31) 0.01 (0.04, 0.03) 0.257
MK-0633 50 mg 214 0.41 (0.34) 0.06 (0.09, 0.03)e 0.268
MK-0633 100 mg 207 0.40 (0.32) 0.05 (0.08, 0.02)e 0.130
CI: confidence interval; FEV1: forced expiratory volume in 1 s; LS: least squares; PEFR: peak expiratory flow rate; SD: standard deviation.
a Based on LDA model with factors for treatment; week (as categorical variable); concomitant corticosteroid stratum; baseline value as
a covariate and a treatment-by-week interaction - Summary over the last 4 weeks of the treatment period.
b Based on ANCOVA model with factors for treatment, concomitant corticosteroid stratum and baseline value as a covariate - Measured
at Week 6.
c FAS restricted to the subset of patients with nighttime symptoms at baseline.
d p-value for Tukey linear trend test through dose level.
e p< 0.05 vs. MK-0633 10 mg.
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p=0.004 MK-0633 vs. placebo through 100 mg by trend test. 
p=0.201 through 50 mg;  p=0.586 through 10 mg. 
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b
Figure 3 Primary efficacy measure: change from baseline in
FEV1 (L) over the last 4 weeks of treatment. A. Over 6 weeks
(primary endpoint). B. Over optional extension periods. Full
analysis set (only includes patients who entered the extensions
for Fig. 2B).
The efficacy and tolerability of Mk-0633, a 5-lipoxygenase inhibitor, in chronic asthma 41AEs (4 AEs of asthma: 2 in placebo group, 1 in MK-0633
10 mg group and 1 in MK-0633 100 mg group; 1 AE of
pyrexia and 1 AE of gastroenteritis in MK-0633 50 mg group;
and AEs of Basal cell carcinoma, Sinusitis and Liver disorder
in MK-0633 100 mg group), 2 of which resulted in discon-
tinuations, one in the MK-0633 50 mg group (pyrexia) and
one in the 100 mg group (asthma). There was 1 serious drug-
related AE in a patient receiving MK-0633 100 mg, who had
approximately 20-fold elevations in ALT and AST, which
gradually returned to normal over several weeks after
discontinuation of study drug. Thirteen (13) patients dis-
continued due to an AE, of which 4 were considered to be
drug-related, 1 in the placebo group (drug eruption), 1 in
the MK-0633 10 mg group (chronic cholecystitis), and 2 in
the MK-0633 100 mg group (liver disorder and rash).
The rate of AEs of interest (discontinuations due to
worsening of asthma and the percentage of patients
meeting NAG discontinuation criteria) was low and similar
between treatment groups (Table 4, Supplementary Tables
4 and 5).
There appeared to be a dose-related trend in AST
and ALT elevations with MK-0633 compared with placebo(Table 5). After these results were unblinded for Period II,
the study extensions were terminated early by the sponsor,
based on an evaluation of the risks versus benefits of
continued treatment. Patients in Periods III and IV at the
time of study termination were discontinued from the
study.
Period III and IV e 24 weeks and 52 weeks
The incidences of clinical AEs and LFT elevations in Periods
III and IV were similar between MK-0633 100 mg and
placebo (Tables 6e8).Discussion
The purpose of this study was to explore the dose-response
efficacy and tolerability of MK-0633, a 5-LO inhibitor,
compared with placebo in adults with chronic asthma. We
found that for the primary endpoint of the change from
baseline in FEV1 over the last 4 weeks of the main 6-week
treatment period, MK-0633 was significantly more effec-
tive than placebo at the 100 mg dose, but not at the 50 mg
dose. For the main study period, MK-0633 at various doses
was also significantly more effective than placebo for
several secondary endpoints. MK-0633 100 mg continued to
be more effective than placebo over the first extension
period for the primary endpoint in addition to most other
efficacy measures, similar to that observed for the main
treatment period. Because of the incidence of LFT abnor-
malities in the main study period, the optional study periods
were terminated by the sponsor. Therefore, efficacy was not
formally evaluated for the second extension period because
of the small sample size due to study termination.
We found that MK-0633 achieved approximately 90%
inhibition of urinary LTE4 at a concentration of approxi-
mately 1200 nM, yet this was associated with a relatively
modest change in FEV1 from baseline. Indeed, based on the
MK-0633 concentration-response curve, the dose-response
plateau for FEV1 was not likely achieved with 100 mg.
Thus, the dose-response for LTE4 and FEV1 were distinct.
Based on the PK/PD modeling of the data from this study,
the dose to achieve a clinically meaningful increase in FEV1
of 120 mL is approximately 4 that required to maximally
inhibit LTE4. The reason for the apparent incongruence
between LTE4 and FEV1 in this study is unclear, and previous
research regarding the relation between LTE4 and asthma
treatment response has been inconsistent. Reiss and
colleagues found that, in patients with exercise-induced
bronchoconstriction, urinary LTE4 concentrations were
significantly higher after exercise challenge in patients
receiving placebo than in those receiving montelukast.21
Similarly, in a study of intravenous montelukast in acute
asthma in an emergency department setting, Green et al.
found LTE4 was significantly elevated during exacerbations
compared with levels at follow-up 2 weeks later.22 They
also found a significant correlation between improvement
in FEV1 and decline in LTE4 over the 2-week period. These
results suggest that antileukotriene agents blunt LTE4
production and that this effect is associated with improved
lung function. Others have also found similar relationships
between LTE4 and lung function and the blunting effect of
montelukast when measured over both relatively brief
Table 3 Other efficacy measures, Full analysis set, Period II.
Treatment N n (%) Adjusted Odds Ratio (95% CI) vs. placebo p-value vs. placeboc
Asthma attacksa
Placebo 236 20 (8.5) e e
MK-0633 10 mg 235 25 (10.6) 1.2 (0.6, 2.2) 0.664
MK-0633 50 mg 235 12 (5.1) 0.5 (0.2, 1.1)d 0.067
MK-0633 100 mg 236 15 (6.4) 0.7 (0.3, 1.4) 0.112
Corticosteroid rescuea
Placebo 236 19 (8.1) e e
MK-0633 10 mg 235 24 (10.2) 1.2 (0.6, 2.3) 0.650
MK-0633 50 mg 235 10 (4.3) 0.4 (0.2, 0.9)d 0.036
MK-0633 100 mg 236 12 (5.1) 0.5 (0.2, 1.2) 0.036
N LS mean (95% CI) p-value vs. placeboa
Percentage of days with an asthma exacerbationb
Placebo 236 16.01 (12.70, 19.32) e
MK-0633 10 mg 235 18.00 (14.68, 21.32) 0.408
MK-0633 50 mg 235 13.96 (10.65, 17.27) 0.387
MK-0633 100 mg 232 12.77 (9.46, 16.09)d 0.066
Percentage of days with asthma controlb
Placebo 236 30.51 (25.94, 35.09) e
MK-0633 10 mg 235 28.97 (24.38, 33.56) 0.624
MK-0633 50 mg 235 36.32 (31.74, 40.91)d 0.077
MK-0633 100 mg 236 31.32 (26.65, 35.77) 0.361
CI: confidence interval; SD: standard deviation.
a based on logistic regression model with terms for treatment, % predicted FEV1 at baseline and concomitant corticosteroid stratum -
Assessed at Week 6.
b based on LDA model with factors for treatment; week (as categorical variable); concomitant corticosteroid stratum; baseline value as
a covariate and a treatment-by-week interaction. - Summary over the last 4 weeks of the treatment period.
c p-value for Tukey linear trend test through dose level.
d p< 0.05 vs. MK-0633 10 mg.
42 Y.S. Wasfi et al.study periods (e.g., 8 days)23 and longer observation
periods (e.g., 4 weeks).24 However, others have found little
or no association between LTE4 and response over longer
period studies (4 weeks to year).25,26
Interestingly, early results with the 5-LO inhibitor
zileuton showed a significant increase in FEV1 (0.32 L) after
4 weeks of treatment despite urinary LTE4 inhibition of only
39%,27 supporting the possibility that changes in urinary
LTE4 and FEV1 may not be highly correlated. It is notable,
however, that in ex vivo whole blood assays, zileuton28
produced greater than 90% LTB4 inhibition, and MK-0633Table 4 Number of patients with adverse experiences, All pati
Placebo
N Z 238 n (%)
MK-0
N Z
Clinical AE 88 (37.0) 93 (3
Drug-related AEa 12 (5.0) 15 (6
Serious AE 2 (0.8) 1 (0
Discontinued due to AE 3 (1.3) 3 (1
Discontinued due to
worsening asthmab
2 (0.8) 0 (0
Discontinued due to NAGb 0 (0.0) 0 (0
AE: adverse experience; NAG: N-acetyl-b-glucosaminidase.
a Determined by the investigator to be drug-related.
b p>0.05 for individual MK-0633 groups vs. placebo and for Cochran-Aat doses 100 mg (data on file) also produced greater
than 90% LTB4 inhibition.
There are several possibilities for these conflicting
findings. First, as Rabinovitch et al. speculated, urinary
LTE4, which represents total body LTE4 is a more general
indicator of inflammatory response,26 and does not accu-
rately represent the concentration at sites of inflammation
such as the small airways. In addition, meaningful associ-
ations between LTE4 and lung function appeared to occur
more commonly in acute asthma, more severe asthma, or
shorter-term studies. Therefore, a significant correlationents as treated, Period II.
633 10 mg
237 n (%)
MK-0633 50 mg
N Z 237 n (%)
MK-0633 100 mg
N Z 238 n (%)
9.2) 83 (35.0) 95 (39.9)
.3) 12 (5.1) 18 (7.6)
.4) 2 (0.8) 4 (1.7)
.3) 3 (1.3) 4 (1.7)
.0) 1 (0.4) 2 (0.8)
.0) 1 (0.4) 1 (0.4)
rmitage trend test vs. placebo.
Table 5 Liver function test elevations, All patients as treated, Period II.
Criterion Placebo MK-0633 10 mg MK-0633 50 mg MK-0633 100 mg
n/N (%) n/N (%) n/N (%) n/N (%)
Alkaline Phosphatase (IU/L)
Increase  100% and >ULN 0/236 (0.00) 0/234 (0.00) 1/232 (0.43) 2/234 (0.85)
Increase  50% and >1.5*ULN 0/236 (0.00) 1/234 (0.43) 0/232 (0.00) 2/234 (0.85)
Increase  50% and >2*ULN 0/236 (0.00) 0/234 (0.00) 0/232 (0.00) 1/234 (0.43)
>3*ULN 0/236 (0.00) 0/234 (0.00) 0/232 (0.00) 0/234 (0.00)
>5*ULN 0/236 (0.00) 0/234 (0.00) 0/232 (0.00) 0/234 (0.00)
Alanine Aminotransferase (IU/L)
Increase  100% and >ULN 7/236 (2.97) 6/233 (2.58) 6/232 (2.59) 17/233 (7.30)
Increase  50% and >1.5*ULN 10/236 (4.24) 7/233 (3.00) 9/232 (3.88) 11/233 (4.72)
Increase  50% and >2*ULN 2/236 (0.85) 5/233 (2.15) 3/232 (1.29) 7/233 (3.00)
>3*ULN 2/236 (0.85) 2/233 (0.86) 0/232 (0.00) 5/233 (2.15)
>5*ULN 0/236 (0.00) 1/233 (0.43) 0/232 (0.00) 2/233 (0.86)
Aspartate Aminotransferase (IU/L)
Increase  100% and >ULN 3/236 (1.27) 3/234 (1.28) 5/232 (2.16) 12/234 (5.13)
Increase  50% and >1.5*ULN 4/236 (1.69) 5/234 (2.14) 8/232 (3.45) 11/234 (4.70)
Increase  50% and >2*ULN 1/236 (0.42) 4/234 (1.71) 3/232 (1.29) 7/234 (2.99)
>3*ULN 0/236 (0.00) 2/234 (0.85) 0/232 (0.00) 6/234 (2.56)
>5*ULN 0/236 (0.00) 1/234 (0.43) 0/232 (0.00) 2/234 (0.85)
Bilirubin (mg/dL)
Increase  100% and >ULN 3/236 (1.27) 3/234 (1.28) 3/232 (1.29) 1/234 (0.43)
Increase  50% and >1.5*ULN 2/236 (0.85) 0/234 (0.00) 2/232 (0.86) 0/234 (0.00)
Increase  50% and >2*ULN 0/236 (0.00) 0/234 (0.00) 1/232 (0.43) 0/234 (0.00)
>3*ULN 0/236 (0.00) 0/234 (0.00) 0/232 (0.00) 0/234 (0.00)
>5*ULN 0/236 (0.00) 0/234 (0.00) 0/232 (0.00) 0/234 (0.00)
ULN Z Upper limit of normal range.
The efficacy and tolerability of Mk-0633, a 5-lipoxygenase inhibitor, in chronic asthma 43between LTE4 and lung function might not be expected in
our 6-week study in moderate chronic asthma.
Our observed mean absolute change in pre-
bronchodilator FEV1 with MK-0633 100 mg was 0.20 L,
which is less than the changes of 0.23 L to 0.36 L observed in
early and pivotal placebo-controlled trials of chronically
administered zileuton.13,27,29 The placebo-adjusted changes
in FEV1 were also smaller with MK-0633 (0.07 L) than for
zileuton (approximately 0.11 L to 0.27 L). However, when
accounting for baseline values, the changes observed with
zileuton ranged from 12% to 16%, compared with a change of
approximately 10%withMK-0633 100mg in the present study.Table 6 Number of patients with adverse experiences, All
patients as treated, Period III.
Placebo
N Z 174 n (%)
MK-0633 100mg
N Z 533 n (%)
Clinical AE 85 (48.9) 253 (47.5)
Drug-related AEa 11 (6.3) 28 (5.3)
Serious AE 1 (0.6) 3 (0.6)
Discontinued due to AE 5 (2.9) 8 (1.5)
Discontinued due to
worsening asthmab
2 (1.1) 4 (0.8)
Discontinued due to
NAGb
0 (0.0) 0 (0.0)
AE: adverse experience.
a Determined by the investigator to be drug-related.
b p> 0.05 for MK-0633 100 mg vs. placebo.The corresponding changes from baseline with placebo were
6e7% in the zileuton studies, and 6% in our study. Thus,
although the absolute changes in FEV1 observed with zileu-
tonwere considerably higher than that observed in our study,
the percentage changes from baseline were reasonably
similar to that observed in our study. This observation, along
with the similar effects of zileuton and MK-0633 on ex vivo
LTB4 inhibition and in FEV1 suggest a generally similar effi-
cacy profile between MK-0633 and zileuton.
There were no differences between treatment groups in
the rates of overall clinical AEs or for the pre-specified AEs of
interest (discontinuations due to worsening asthma or due to
NAG). However, we observed a dose-dependent increase in
the proportion of patients with ALT and AST elevations with
MK-0633 compared with placebo during the main treatment
period. Preclinical testing inmice at doses approximately 3
the maximal human AUC showed minimal treatment-related
increases in ALT (<2 ULN), which was thought to be the
result of adaptive response to enzyme induction. However,
there were no transaminase changes in rats or dogs with
doses of MK-0633 at exposures that were at least 7 the
human exposure at the “no observed adverse effect level”.
As such, LFT abnormalities were not expected in humans,
and thus, the exact basis of the apparent dose-related LFT
elevations in Period II of the present study is unclear. Even
more interestingly, the prevalence of LFT elevations during
the extension periods was numerically greater in the
placebo group than in the MK-0633 100 mg group, and
a recent trial of MK-0633 100 mg in chronic obstructive
pulmonary disease showed no difference in LFT elevations
Table 7 Number(%) of Patients with LFT Elevation, All patients as treated, Period III.
Criterion Placebo MK-0633 100 mg
n/N (%) n/N (%)
Alkaline Phosphatase (IU/L)
Increase  100% and >ULN 1/170 (0.59) 4/527 (0.76)
Increase  50% and >1.5*ULN 0/170 (0.00) 5/527 (0.95)
Increase  50% and >2*ULN 0/170 (0.00) 3/527 (0.57)
>3*ULN 0/170 (0.00) 1/527 (0.19)
>5*ULN 0/170 (0.00) 0/527 (0.00)
Alanine Aminotransferase (IU/L)
Increase  100% and >ULN 15/170 (8.82) 37/525 (7.05)
Increase  50% and >1.5*ULN 12/170 (7.06) 29/525 (5.52)
Increase  50% and >2*ULN 8/170 (4.71) 15/525 (2.86)
>3*ULN 1/170 (0.59) 3/525 (0.57)
>5*ULN 0/170 (0.00) 1/525 (0.19)
Aspartate Aminotransferase (IU/L)
Increase  100% and >ULN 11/170 (6.47) 23/527 (4.36)
Increase  50% and >1.5*ULN 12/170 (7.06) 24/527 (4.55)
Increase  50% and >2*ULN 8/170 (4.71) 14/527 (2.66)
>3*ULN 1/170 (0.59) 7/527 (1.33)
>5*ULN 1/170 (0.59) 2/527 (0.38)
Bilirubin (mg/dL)
Increase  100% and >ULN 4/170 (2.35) 6/527 (1.14)
Increase  50% and >1.5*ULN 1/170 (0.59) 5/527 (0.95)
Increase  50% and >2*ULN 1/170 (0.59) 1/527 (0.19)
>3*ULN 1/170 (0.59) 0/527 (0.00)
>5*ULN 0/170 (0.00) 0/527 (0.00)
ULN Z Upper limit of normal range.
44 Y.S. Wasfi et al.versus placebo.30 The pattern of LFT elevations in this study
was that of asymptomatic, isolated ALT (and AST) elevations
without associated alkaline phosphatase or bilirubin eleva-
tions, which is consistent with idiosyncratic hepatocellular
injury, similar to that observed with zileuton.13,14,29,31,32
This pattern and the lack of hepatic findings in preclinical
or other clinical studies with MK-0633 suggest that theremay
be a class effect of 5-LO inhibitors on hepatic function,
although additional investigations would be necessary for
confirmation.
The efficacy observed with both zileuton and MK-0633
suggest that antileukotriene synthesis inhibitors may have
a role in asthma treatment. Because zileuton and other
antileukotriene synthesis inhibitors have never been
directly compared with CysLT antagonists in a study ofTable 8 Number of patients with adverse experiences, All
patients as treated, Period III and IV.
Placebo
N Z 50 n (%)
MK-0633 100mg
N Z 166 n (%)
Clinical AE 27 (54.0) 100 (60.2)
Drug-related AEa 5 (10.0) 17 (10.2)
Serious AE 0 (0.0) 1 (0.6)
Discontinued due to AE 1 (2.0) 4 (2.4)
Discontinued due to
worsening asthma
1 (2.0) 1 (0.6)
AE: adverse experience.
a Determined by the investigator to be drug-related.chronic asthma, the relative efficacy benefit of inhibiting
leukotriene synthesis versus CysLT antagonism is unknown.
In conclusion, in patients with chronic asthma, MK-0633
was associated with a statistically significant but modest
improvement in FEV1 compared with placebo that was
maintained for at least 24 weeks. There appeared to
a dose-related increase in liver transaminases. The overall
benefit-risk ratio did not support the clinical utility of MK-
0633 in asthma.
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